Member News provides an opportunity for SDEE members to share news and announcements. This month's Member News features:
- Sandhill Crane Diagnostics (Syliva Norman)
- Lysulin (John Burd)
- ProBack Office (Jennifer Barnes)
- Abreos Bioscience
- Jaan Biotherapeutics (Bhawanjit Brar)
- Wagenknecht IP Law Group
- United BioChannels (Jeff Whitmore)
Sylvia Norman, Sandhill Crane Diagnostics
Sandhill Crane Diagnostics is developing a connected, rapid, medical testing platform for use in rural and low-resource clinics, disaster relief healthcare and in-home caregiver settings. We are pleased to announce our recent acceptance into the Murrieta Innovation Center and The Brink accelerator at USD.
Lysulin, John Burd
A new member to SDEE is Lysulin, Inc. Lysulin is the first in class, all-natural nutritional anti-glycation supplement for people with diabetes; now available OTC without a prescription. In August, Lysulin presented data at the American Association of Diabetes Educators from a double blind placebo controlled study that showed the dramatic benefit seen in people with Type 2 diabetes taking Lysulin.
ProBack Office, Jennifer Barnes
Pro Back Office is a 2018 SDBJ Best Places to Work for medium-sized businesses (50-249 employees). The San Diego Business Journal’s Best Places to Work Awards recognize outstanding companies whose benefits, policies and practices are among the best in San Diego. One hundred companies were selected as the 2018 Best Places To Work. For the 2nd Time, Pro Back Office, LLC Appears on the Inc. 5000, Ranking No. 1710 With Three-Year Revenue Growth of 267 Percent.
Pro Back Office, LLC is No. 1710 on the 37th annual Inc. 5000, the most prestigious ranking of the nation’s fastest-growing private companies. Pro Back Office provides highly skilled operational accounting, finance and strategic consulting talent, experience and expertise. PBO serves start-ups, emerging, public, private, government and non-profit organizations and businesses. Whether your organization needs a bookkeeper or a CFO, or a business advisory and comprehensive governance, risk and compliance expert, PBO services are available on an hourly, part-time and project basis. PBO personnel are available on site or remotely. There are more than 60 professionals on staff to serve clients throughout the Pacific Southwest region. For more information, visit www.probackoffice.com.
Abreos Biosciences, a personalized medicine company that, for the last 5 years, has been developing precision dosing technologies for biologic drugs. In August, they announced the launch of their first commercial product: moNATor - an FDA marked Laboratory Diagnostic Test for Natalizumab (Tysabri). (Link to PR)
Abreos Biosciences continues its mission to develop quality products that serve to connect the right patients to the right drugs at the right dose. Personalized monitoring starts with a simple blood test. Specifically for Tysabri, a Multiple Sclerosis drug that has a black-box label for it's risk for PML (a deadly brain disease), the moNATor test was designed to compliment that therapy by:
- identifying the appropriate dosing interval for each patients
- help monitor patients for drug efficacy and safety risk
- Reduce excessive cost to payors and patients
Abreos' commitment to quality has lead to a partnership with ResearchDx, a CLIA/CAP certified laboratory known for designing, developing, and manufacturing world-class companion diagnostics. (PR Link)
The moNATor test for MS patients on Natalizumab (Tysabri) is but the first in a pipeline of value-based products. Abreos Biosciences invites you to be their partner in health and connect with a community of hundreds of patients already benefiting from personalized dosing.
Bhawanjit Brar CEO, Jaan Biotherapeutics
Jaan Biotherapeutics, a San Diego founded pre-clinical stage biopharmaceutical company was approached by Nature to feature as a company in Nature’s BioPharma Dealmakers September Issue on the latest developments regenerative medicine. Jaan‘s article has been published in Nature Biotechnology and Nature Reviews Drug Discovery (100,000+ print readers) and shows some of our MRI data in mice treated with our lead drug candidate JN-101. Please read our Mini Report in Nature BioPharma Dealmakers by following the link: https://biopharmadealmakers.nature.com/users/177830-jaan-biotherapeutics/posts/38834-healing-the-heart-by-manipulating-micrornas
Wagenknecht IP Law Group
There are 5 spaces left for the October 23rd SDEE/Wagenknecht Lunch & Learn: “Strategies for Protecting Life Science Inventions.” This is a complimentary workshop from 12:00 PM – 1:30 PM at Wells Fargo Bank in UTC. Speakers will be patent attorneys, Ray Wagenknecht and Antony Novom. Please RSVP to “Andy” Kotner, firstname.lastname@example.org if you would like to attend.
United BioChannels (Jeff Whitmore)
United BioChannels partners with Biodesy to expand commercialization. As part of their Series C financing, Biodesy has dedicated funds to expanding commercial efforts. Over the last four months the company has partnered with United BioChannels, a life science brand management company, to explore applications and customer needs, and to refine Biodesy’s value proposition and messaging. To increase access to Biodesy’s novel technology to detect structural changes in biological molecules and the Delta™ System, Biodesy will further grow its fee-for-service engagement efforts. In partnership with United BioChannels, Biodesy will expand reach in North America and Europe to increase industry adoption of the technology. http://www.biodesy.com/news/biodesy-partners-united-biochannels/